Arovella Therapeutics Limited (ASX:ALA)

3.8¢

right-arrow Created with Sketch. -0.002 (-5%)
MCAP $18.27M
Last trade 16.10pm 26/11/2021 20mins delayed

Latest Announcements

17/11/2021ALAArovella Therapeutics Limited
15/11/2021ALAArovella Therapeutics Limited
15/11/2021ALAArovella Therapeutics Limited
11/11/2021ALAArovella Therapeutics Limited
11/11/2021ALAArovella Therapeutics Limited
11/11/2021ALAArovella Therapeutics Limited
10/11/2021ALAArovella Therapeutics Limited
10/11/2021ALAArovella Therapeutics Limited

Company Overview

Arovella Therapeutics Limited, formerly SUDA Pharmaceuticals Limited, is an Australia-based biotechnology company. The Company focuses on specific disease areas, oncology and conditions that affect the central nervous system. It is focused on developing therapies to treat human disease. The Company is developing its invariant natural killer T (iNKT) cell therapy platform to treat blood cancers. The Company's OroMist technology develops oral sprays to reformulate pharmaceuticals. Its ZolpiMist oral spray formulation of zolpidem tartrate to treat short-term insomnia. It is also developing oral sprays to treat migraine headaches, motion sickness, and drug-resistant epilepsy.

Search Previous Announcements